Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Az intermitáló hypoxia hatása a hurokerősítésre egészséges személyekben (HI-LOOP)

2026. november 17. frissítette: Poitiers University Hospital

Az Intermittáló Hypoxia Hatása a Loop Gain-re Egészséges Alanyoknál

Sleep apnoea-hypopnoea syndrome (SAHOS), which causes numerous comorbidities, particularly cardiovascular ones, is widespread worldwide today and incurs significant healthcare costs.

Current research in this field focuses on identifying different phenotypes in affected patients in order to provide more personalised treatment.

One of these phenotypes appears to be linked to instability in ventilatory control due to an increase in loop gain (LG) in these subjects.

However, the pathophysiology of this ventilatory control instability due to increased LG is not fully understood. It is still difficult to determine whether subjects have an intrinsically high LG or if exposure to intermittent hypoxia during OSA promotes an increase in LG.

It has also been demonstrated that OSA causes vascular hyperreactivity by increasing oxidative stress through elevated ROS production. This leads to endothelial dysfunction in response to intermittent hypoxia associated with apnoea. Extracellular vesicles (microvesicles and exosomes) have been shown to play a role in this endothelial response. These extracellular vesicles are essential for intercellular communication in both physiological and pathological situations, such as SAHOS.

Therefore, the objective of this research is to determine whether exposure to intermittent hypoxia and changes in microvesicle phenotype could influence LG, which could lead to new therapeutic advances in the context of SAHOS.

A tanulmány áttekintése

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

40

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányozza a kapcsolattartók biztonsági mentését

Tanulmányi helyek

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év (Felnőtt)

Egészséges önkénteseket fogad

Igen

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • Healthy subjects aged 18 to 45
  • BMI between [18-25] kg/m2
  • No known sleep disorders
  • Free subjects, not under guardianship or curatorship or subordination
  • Persons affiliated with or beneficiaries of a Social Security scheme
  • Signature of informed consent after clear and honest information about the study

Non-inclusion Criteria:

  • Active smoking or cessation within the last 3 months and total consumption > 10 pack-years
  • Alcohol or drug addiction
  • Excessive coffee consumption (> 3 espressos/day)
  • History of acute mountain sickness (presence of symptoms such as dizziness, headaches, nausea/vomiting, and incapacitating fatigue during or after a stay at high altitude)
  • Living at high altitude (above 3,000 meters, continuously for more than 6 months during the last 10 years)
  • History of respiratory and/or cardiovascular and/or renal and/or neurological disease (migraines, epilepsy)
  • Diabetes
  • Anemia, sickle cell anemia
  • Any medication associated with oxygen metabolism and any psychotropic medication (anxiolytics, sedatives, antidepressants, neuroleptics, muscle relaxants, etc.) that may interfere with motor and respiratory control, muscle strength, or sleep quality
  • Women of childbearing age who do not use effective contraception (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy)
  • Concurrent participation in another clinical research study affecting respiratory control or respiratory muscles
  • Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by judicial or administrative decision, persons staying in a healthcare facility

Post-inclusion exclusion criteria:

  • SpO2 < 97% in ambient air at rest.
  • Detection of pregnancy in women of childbearing age.
  • Detection of acute mountain sickness (Lake Louise score > 0).
  • Abnormalities in spirometry, ventilatory polygraphy, electrocardiogram, and/or hemoglobinometry prior to randomization.
  • Ventilation minute signal, PETCO2 or PETO2 unusable.
  • Irreversible deterioration in the volunteer's health during the study period, likely to affect the experimental conditions.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Megelőzés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Crossover kiosztás
  • Maszkolás: Egyetlen

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Arm A : ambient air then intermittent hypoxia

T1 : Conduct the experiment in ambient air (without hypoxia) for six hours. T2 : Then, after a washout period of at least seven days, conduct the experiment in intermittent hypoxia via the hypoxia chamber for six hours.

The volunteer will remain at rest in the hypoxic chamber, experiencing intermittent hypoxic conditions cyclically every 6 minutes. During one third of the cycle, they will be exposed to hypoxia in order to reduce SpO₂ to between 85% and 90%. Then, during two thirds of the cycle, they will receive oxygenation at a rate of 1 L/min (with possible subject-dependent modulations), with the aim of achieving an SpO₂ of greater than 95%.

To make the hypoxia intermittent, the volunteer will also be given a medium-concentration oxygen mask that provides intermittent airflow, controlled by the D-6341 mass flow controller.

The participant will remain at rest in the hypoxic chamber under normoxic conditions. To prevent the volunteer from becoming aware of the conditions to which they are exposed, an air flow rate of 1 L/min will be used to simulate intermittent oxygenation.

Kísérleti: Arm B : intermittent hypoxia then ambient air

T1 : Conduct an experiment involving intermittent hypoxia in the hypoxia chamber for six hours.

T2 : Then, after a washout period of at least seven days, conduct an experiment involving ambient air (without hypoxia).

The volunteer will remain at rest in the hypoxic chamber, experiencing intermittent hypoxic conditions cyclically every 6 minutes. During one third of the cycle, they will be exposed to hypoxia in order to reduce SpO₂ to between 85% and 90%. Then, during two thirds of the cycle, they will receive oxygenation at a rate of 1 L/min (with possible subject-dependent modulations), with the aim of achieving an SpO₂ of greater than 95%.

To make the hypoxia intermittent, the volunteer will also be given a medium-concentration oxygen mask that provides intermittent airflow, controlled by the D-6341 mass flow controller.

The participant will remain at rest in the hypoxic chamber under normoxic conditions. To prevent the volunteer from becoming aware of the conditions to which they are exposed, an air flow rate of 1 L/min will be used to simulate intermittent oxygenation.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
The change in Loop Gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air).
Időkeret: 6 hours of experimental condition

Loop gain is the product of 'controller gain' (ventilatory responsiveness to CO₂ above eupnoea) and 'plant gain' (the ventilatory increase required for a given reduction in PaCO₂).

The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate).

For each experimental condition (test-hypoxia or control-ambient air), loop gain will be measured before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber).

The change in loop gain is defined as the difference between the average values (over 5 minutes) of the loop gain before and after the experimentation.

6 hours of experimental condition

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
The change in controller gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)
Időkeret: 6 hours of experimental condition

The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate).

For each experimental condition (test-hypoxia or control-ambient air), controller gain will be assessed before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber).

The change in controller gain is defined as the difference between the average values (over 5 minutes) of the controller gain before and after experimental condition.

6 hours of experimental condition
The change in plant gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)
Időkeret: 6 hours of experimental condition

The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate).

For each experimental condition (test-hypoxia or control-ambient air), plant gain will be assessed before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber).

The change in plant gain is defined as the difference between the average values (over 5 minutes) of the plant gain before and after experimental condition.

6 hours of experimental condition
The change in the quantity of extracellular vesicles before and after 6 hours of experimental condition (intermittent hypoxia versus ambient air)
Időkeret: 6 hours of experimental condition

The quantity of extracellular vesicles is assessed from blood samples using flow cytometry with specific antibodies. Blood samples are collected before the experimental condition (after 30 minutes of rest) and after the experimental condition (after leaving the hypoxic chamber).

This change is expressed as the difference in the following extracellular vesicle concentrations before and after experimental conditioning:

  • EVs from platelets expressing CD41
  • EVs from erythrocytes expressing CD235a
  • EVs from leukocytes expressing CD45
  • EVs from endothelial cells expressing CD146
  • EVs from granulocytes expressing CD66b and CD11b
  • EVs from activated leukocytes expressing CD62L
  • EVs from activated endothelial cells expressing CD62E
  • EVs from activated platelets expressing CD62P
  • CD62P/platelet ratio
  • EVs carrying the PSGL-1 ligand expressing CD162
  • EVs carrying phosphatidylserine expressing annexin V
6 hours of experimental condition
Correlation between the change in quantity of extracellular vesicles and change in loop gain
Időkeret: 6 hours of experimental condition

The change in the quantity of extracellular vesicles is defined as the difference of the extracellular vesicle concentration before and after the experimental condition (intermittent hypoxia and ambient air). The change in loop gain is defined as the difference of the loop gain values before and after the experimental condition (same definition as the primary outcome).

We are interested in the following extracellular vesicles: CD41, CD235a, CD45, CD146, CD66b, CD11b, CD62L, CD62E, CD62P and CD62/platelet annexin V.

6 hours of experimental condition
Change in loop gain before and after experimental condition (intermittent hypoxia or ambient air), in the subgroup of patients with hyperventilation syndrome and in the subgroup of patients without hyperventilation syndrome.
Időkeret: 6 hours of experimental condition

The change in loop gain is defined in the same way as the primary endpoint, i.e. as the difference between the measurements taken before and after the experimental condition. Hyperventilation syndrome is defined as a Nijmegen score of 23 or above at the inclusion visit.

6 hours of experimental condition

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. október 20.

Elsődleges befejezés (Becsült)

2027. december 1.

A tanulmány befejezése (Becsült)

2027. december 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. február 6.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. február 12.

Első közzététel (Tényleges)

2026. február 13.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 20.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 17.

Utolsó ellenőrzés

2026. november 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Kulcsszavak

Egyéb vizsgálati azonosító számok

  • HI-LOOP
  • 2025-A02282-47 (Egyéb azonosító: French Ethics Committee (Comité de Protection des Personnes))

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

ELDÖNTETLEN

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel